Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

353.70 11.12 −3.05%
Market cap
$9.8B
P/E
42.5×
Fwd P/E
35.4×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(9.50%) 10.84% 2.50% 3.11%
Piotroski F-Score
5 5 7 5
ROA
(6.66%) 7.62% 1.75% 2.17%
ROIC
2.15% 0.41% 0.55% 0.49%
Return on Tangible Assets
(23.63%) 25.94% 6.61% 8.63%
Average Days of Receivables
66.32 65.08 60.07 62.28
Free Cash Flow per Share
12.51 13.74 13.26 13.20
Free Cash Flow
336.90 374.70 357.40 353.10
Other line items

Show all line items

Columns are period end dates